Insulet Corporation $PODD Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management cut its Insulet stake by 67.2% in the second quarter, selling 173,086 shares and retaining 84,633 shares worth approximately $12.9 million.
• Insulet exceeded second-quarter expectations, reporting $1.66 in EPS and $801.7 million in revenue, with revenue up 23.5% year over year. However, the company lowered its fiscal 2026 revenue outlook, raising concerns about future growth momentum.
• Analyst sentiment remains mixed: several firms reduced their price targets, while the consensus rating is “Hold” with an average target of $195.40, above the stock’s reported price of $142.85.

Assenagon Asset Management S.A. trimmed its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 67.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 84,633 shares of the medical instruments supplier's stock after selling 173,086 shares during the quarter. Assenagon Asset Management S.A. owned about 0.12% of Insulet worth $12,885,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trust Asset Management LLC acquired a new position in Insulet in the 2nd quarter worth approximately $119,000. Avior Wealth Management LLC acquired a new stake in Insulet during the 2nd quarter valued at approximately $265,000. CX Institutional boosted its holdings in shares of Insulet by 149.9% in the 2nd quarter. CX Institutional now owns 2,132 shares of the medical instruments supplier's stock valued at $325,000 after acquiring an additional 1,279 shares during the last quarter. Basecamp Wealth Advisors LLC boosted its holdings in shares of Insulet by 48.3% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier's stock valued at $66,000 after acquiring an additional 102 shares during the last quarter. Finally, Empowered Funds LLC increased its stake in shares of Insulet by 38.1% in the first quarter. Empowered Funds LLC now owns 2,880 shares of the medical instruments supplier's stock worth $604,000 after acquiring an additional 795 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PODD. Barclays reduced their target price on shares of Insulet from $286.00 to $198.00 and set an "underweight" rating for the company in a report on Thursday, May 7th. Jefferies Financial Group lowered their price target on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Citigroup increased their price target on Insulet from $165.00 to $172.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 8th. UBS Group reduced their price objective on Insulet from $174.00 to $150.00 and set a "neutral" rating for the company in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Insulet presently has a consensus rating of "Hold" and an average price target of $195.40.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, supported by strong demand for its Omnipod insulin-delivery system and improved margins. The earnings beat indicates that underlying demand and profitability remain healthy. PODD’s Q2 Earnings Top Estimates, FY’26 Sales View Cut
• Neutral Sentiment: Rosen, Faruqi & Faruqi, the DJS Law Group, Schall Brown & Schwartz, and the Law Offices of Howard G. Smith reminded investors of a pending securities class action and the August 31, 2026, deadline to seek lead-plaintiff status. The announcements largely repeat the same legal information and are not evidence that the claims have been proven. Faruqi & Faruqi Insulet Investor Reminder
• Negative Sentiment: Insulet reduced its fiscal 2026 revenue outlook despite beating quarterly estimates. The lowered sales forecast raises concerns about growth momentum and was identified as the main reason the stock remained under pressure after the earnings release. Insulet Q2 Earnings and Fiscal 2026 Outlook
• Negative Sentiment: Stifel, Benchmark, UBS, and TD Cowen all lowered their price targets to $180, $185, $150, and $144, respectively. JPMorgan reiterated a “Neutral” rating, while Wall Street Zen cut the stock to “Hold,” signaling more cautious expectations for PODD. Analyst Price Target Changes

Insulet Trading Up 1.2%

PODD stock opened at $142.85 on Tuesday. The company's 50-day simple moving average is $155.31 and its 200-day simple moving average is $191.94. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The firm has a market cap of $9.91 billion, a P/E ratio of 26.70, a PEG ratio of 1.04 and a beta of 1.10.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.Insulet's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the business's stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company's stock, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.36% of the company's stock.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source